arrow
A

Adrian F. Hernandez

duke clinical research institute
H指数:134
被引数:8.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Obesity and Change in NT-proBNP with Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and a Worsening Heart Failure Event: PARAGLIDE-HF

肥胖及血管紧张素-中性肽链内切酶抑制对轻度射血分数降低或保留的心力衰竭患者N末端B型利钠肽原变化及心力衰竭恶化事件的影响:PARAGLIDE-HF研究

2026-10-120
PRE
Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk

口服NLRP3抑制剂ruvonoflast在心血管风险升高人群中的抗炎作用

JACC
IF0
2026-05-260
OAAI
From Zero to Zero Sum

从零到零和

2025-10-310
PRE
Deep learning chest X-ray age, epigenetic aging clocks, and associations with age-related subclinical disease in the Project Baseline Health Study

深度学习胸部X光年龄、表观遗传衰老时钟,以及与年龄相关亚临床疾病的关联性——基于Project Baseline健康研究

2025-10-010
PRE
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension

克服开发与实施新型高血压疗法的障碍

2025-10-010
PRE
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI

心力衰竭伴或不伴糖尿病和慢性肾脏病的患者接受心肌梗死后 empa gliflozin 治疗的疗效:来自 EMPACT-MI 的启示

2025-09-140
OAAI
Developing Therapeutics for Rare Cardiovascular Diseases

开发罕见心血管疾病的疗法

2025-09-120
PRE
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

维利西呱用于射血分数降低的心力衰竭患者:VICTORIA和VICTOR试验的个体参与者数据分析

2025-08-300
OAAI
Dapagliflozin, Heart Failure, and Duration of Diabetes

达格列净、心力衰竭和糖尿病持续时间

2025-08-290
OAAI
Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification

评估射血分数降低的心力衰竭患者的获益:使用新型预后风险分层对VICTORIA试验的分析

2025-08-280
OA
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

实现射血分数和达格列净在射血分数改善型心力衰竭中的效果

2025-08-190
OAAI
Geographic Variation and Human Development Index in Heart Failure With Reduced Ejection Fraction

地理变异与射血分数降低的心力衰竭中的人类发展指数

2025-07-110
OA
Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction

EMPACT-MI试验的二次分析揭示了急性心肌梗死后恩格列净的心血管-肾脏有效性和安全性。

2025-06-130
OAAI
Structural abnormalities and effects of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial

结构性异常和沙库必利/缬沙坦在轻度射血分数降低或保留及心力衰竭恶化的患者中的效果:PARAGLIDE-HF试验

2025-05-220
PRE